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Summary
In humans, thromboxane (TX) A 2 signals through the TPα and TPβ isoforms of the TXA 2 receptor that exhibit common and distinct roles. For example, Gq/phospholipase (PL)Cβ signaling by TPα is directly inhibited by the vasodilators prostacyclin and nitric oxide (NO) whereas that signaling by TPβ is unaffected. Herein, we investigated whether TPα and/or TPβ regulate G 12 /Rho activation and whether that signaling might be differentially regulated by prostacyclin and/or NO. Both TPα and TPβ independently regulated RhoA activation and signaling in clonal cells over-expressing TPα or TPβ and in primary human aortic smooth muscle cells (1 o AoSMCs). While RhoA-signaling by TPα was directly impaired by prostacyclin and NO through protein kinase (PK)A-and PKG-dependent phosphorylation, respectively, signaling by TPβ was not directly affected by either agent. Collectively, while TPα and TPβ contribute to RhoA activation, our findings support the hypothesis that TPα is involved in the dynamic regulation of haemostasis and vascular tone, such as in response to prostacyclin and NO. Conversely, the role of TPβ in such processes remains unsolved. Data herein provide essential new insights into the physiologic roles of TPα and TPβ and, through studies in AoSMCs, reveal an additional mode of regulation of VSM contractile responses by TXA 2 .
Introduction:
The phosphorylation status of myosin light chain (MLC) of the actomyosin complex plays a central role in regulating the various types of cytoskeletal reorganizations that widely occur within the vasculature including in platelet shape change and aggregation, tonic-or agonist-induced contraction and relaxation of smooth muscle cells (SMCs), cell migration, cell proliferation and stress fibre formation [1] . Many of the physiologic regulators of platelets and vascular smooth muscle (VSM) contraction, including thromboxane (TX) A 2 , thrombin, ADP, prostaglandin (PG) I 2 or PGD 2 , act through specific G protein coupled receptor (GPCR) -effector systems [1] .
While agents such as TXA 2 and thrombin that promote platelet activation or SMC contraction induce Gq-dependent phospholipase (PL)Cβ activation to evoke calcium (Ca 2+ ) -dependent activation of myosin light chain kinase (MLCK) and MLC 20 phosphorylation [1, 2] , they may also engage the Ca 2+ -independent pathway involving receptor co-coupling to G 12 and RhoA signalling [1] . G 12 members, particularly Gα 13 , activate RGS (regulators of G protein signaling)-box containing members of the Rho guanine nucleotide exchange factor (RhoGEF) family, such as p115 RhoGEF, PDZ RhoGEF or LARG, to activate RhoA and its key effector in this system Rho kinase 1 (also known as p164 ROKα/ROCK2) and 2
(p160 ROKβ/ROCK1), herein termed Rho kinase/ROCK [3] [4] [5] . Rho kinases, in turn, phosphorylate, and inactivate, myosin phosphatase, MLC itself and the myosin phosphatase inhibitor CPI-17 resulting in the Ca 2+ -independent increase in overall levels of phosphorylated MLC through a Rho/Rho kinase-mechanism [2, 4, 5] . Other targets of Rho kinase include its phosphorylation-dependent activation of LIM kinases which, in turn, phosphorylate and inactivate the actin depolymerizing agent cofilin [4] . The central importance of the Ca 2+ independent mechanism of contraction within the vasculature has been highlighted through findings that disorders of the Rho/Rho kinase pathway are major underlying causes of hypertension, vascular spasm and atherosclerosis making Rho kinase an important therapeutic target in the treatment of these diseases [1, 2, 6] .
The prostanoid TXA 2 plays an essential role within the vasculature inducing a diversity of cellular responses including platelet shape change, secretion and aggregation, VSMC contraction and migration and is widely implicated in a number of cardiovascular disorders including thrombosis, hypertension, vessel remodelling and atherosclerotic progression [7] . As a predominantly Gq/PLCβ-coupled GPCR, the TXA 2 receptor or TP can induce both Ca 2+ -dependent and G 12/13 -mediated RhoA / Ca 2+ independent responses platelets and VSMCs [1, 8] . For example, platelets from Gα 13 -deficient mice do not undergo RhoAdependent shape change in response to low levels of TXA 2 but retain the ability to undergo Gq/Ca 2+ -dependent shape change and aggregation at higher agonist concentrations [9] . Similarly, both Ca 2+ -dependent/PLCβ and Ca 2+ -independent/RhoA mechanisms contribute to TXA 2 -induced contraction in isolated bovine aortic (Ao) SMCs and in VSM tissue from various other species [10] [11] [12] . Notably however, in humans, but not in non-primates, TXA 2 actually signals through two distinct TXA 2 receptor isoforms termed
TPα and TPβ that arise through alternative splicing and differ exclusively in their carboxyl-terminal (C tail) domains [13] [14] [15] . Whilst it is currently unknown whether TPα or TPβ independently or indeed differentially modulate RhoA activation and down-stream signaling, there is substantial evidence that the TPα and TPβ isoforms can differentially regulate other cellular effectors raising that possibility [16] [17] [18] [19] [20] [21] .
While both TPα and TPβ are predominantly coupled to Gq/PLCβ activation [22] , they can independently regulate other secondary effector systems including opposite regulation of adenylyl cyclase via
Gs and Gi, respectively [23] . Additionally, TPα, but not TPβ, couples to PLCδ activation via Gh/tissue transglutaminase [24] . Whereas both TPs are expressed in VSMCs, TPα is the predominant isoform expressed in human platelets [25, 26] . Consistent with this, in studies investigating intermolecular cross talk between the pro-aggregatory TXA 2 and the inhibitory prostanoid prostacyclin (PGI 2 ), it was established that Gq/PLCβ coupling and signaling by TPα, but not TPβ, undergoes prostacyclin-induced desensitization mediated through direct cAMP-protein kinase (PK) A phosphorylation of TPα at Ser 329 within its unique Ctail domain [21, 27] . Moreover, Gq/PLCβ signaling by TPα, but not TPβ, is also desensitized by the platelet antagonist /vasodilator nitric oxide (NO), involving direct NO/cGMP-dependent PKG phosphorylation of TPα also within its unique C-tail [20] The implication from these studies is that TPα plays a critical role in vascular haemostasis acting as the major TP target for regulation/inhibition by prostacyclin and NO, such as within the anucleate platelet that predominantly expresses TPα. However, the impact of such direct inhibitory effects of prostacyclin and NO mediated by PKA and PKG, respectively, on signaling by ,TPα S331A and TPα S329,331A respectively, have been previously described [20, 21] . For transfections, HEK 293 cell lines were routinely plated 48 hr previously at ~ 2 x 10 6 cells/10 cm dish in 8 ml media and co-transfected with 10 µg of pADVA and 25 µg of pCMV-based mammalian expression vector using the calcium phosphate/DNA co-precipitation procedure [20] .
Primary (1 o ) human aortic smooth muscle cells (1 o h.AoSMCs) were purchased from Cascade Biologics (C-007-5C) and routinely grown in Smooth Muscle Cell Growth Medium 2 (Promocell GMBH, C-22062) supplemented with 0.5 ng/ml epidermal growth factor, 2 ng/ml basic Fibroblast growth factor, 5 µg/ml insulin, 5% FBS.
Calcium measurements.
Measurements of intracellular calcium ([Ca 2+ ] i ) mobilization were carried out in FURA2/AM preloaded HEK 293 cell lines transiently co-transfected with pCMV:Gαq and pADVA some 48 hr previously, as described [20] . Cells were stimulated with 1 µM U46619, 1 µM Cicaprost, 1 µM BW245C, 5 µM SIN-1 or 10 µM FK409, unless otherwise specified. Data (Supplemental Figures 1 and 2 
Determination of RhoA Activation and Cofilin Phosphorylation.
Activated cellular Rho was determined by interaction with a purified glutathione-S-transferase: rhotekin Rho-binding domain (GST-RBD) fusion protein immobilized on Glutathione-Sepharose 4B resin [28] .
Preparation of the GST-RBD protein was carried out as previously reported [28] . and aliquots (600 µl) were subjected to pull-down using Glutathione-Sepharose 4B beads preloaded with 30
µg GST-RBD, essentially as previously described [28] . Following washing, precipitated GTP-bound RhoA was subjected to SDS-PAGE on 12.5% acrylamide gels and immunoblotted with anti-RhoA monoclonal antibody (Sc-418), followed by chemiluminescence detection [21] . In parallel, to confirm equivalent RhoA protein expression in the cell lysates and uniform protein loading, aliquots of whole cell lysates (typically 10 µl, corresponding to 1.25% of total cell lysate) were directly immunoblotted with the anti-RhoA antibody and / or with the anti-HDJ2 antibody. Similarly, to assess U46619-mediated cofilin phosphorylation and activation, aliquots of whole cells lysates (typically 10 µl, corresponding to 1.25% of total cell lysate) were first immunoblotted with anti-phospho Ser3 cofilin antibody; thereafter, phospho-cofilin blots were stripped and rescreened versus anti-cofilin antibody to normalise for total cofilin protein expression and/or with the anti-HDJ2 antibody to confirm uniform protein loading in each of the assays. All images of RhoA expression/pulldown or cofilin phosphorylation and/or expression were captured using Adobe Photoshop (V6), where band width and intensity was quantified and represented as fold increases relative to basal levels. To account for biological variations in basal activation levels, experiments were normalised to within a comparable range based on measurements from more then 20 individual experiments for each cell type.
F-Actin Staining.
HEK 293 cel, lines or 1 o h.AoSMCs, grown on coverslips for 3 days to achieve approximately 50% confluency, were serum-starved for 2 hr in growth media containing 0.1% FBS, prior to stimulation with U46619 (0 -1 µM; typically 10 nM U46619). To assess the role of prostacyclin or NO, cells were preincubated for 10 min with either 0.01 -10 µM Cicaprost or 0.05 -50 µM SIN-1 before stimulation with U46619 (typically 10 nM for 10 min). F-actin polymerization was stained by the addition of Alexa Fluor® 488 phalloidin essentially as described by the supplier (Molecular Probes) and slides were imaged using an Similarly, 1° h.AoSMCs were screened, under permabilising conditions, by indirect immunofluorescence microscopy for TPα and TPβ expression using affinity purified isoform specific rabbit anti-TPα (3 µg/ml) and anti-TPβ (3 µg/ml) antibodies [30] 
Data analyses
Radioligand binding data was analyzed using GraphPad Prism V3.0 to determine the Kd and B max values.
Statistical analyses were carried out using the unpaired Student's t test using the Statworks Analysis
Package. p-Values of less than or equal to 0.05 were considered to indicate a statistically significant difference. Throughout the figures, * < 0.05, ** < 0.01, *** < 0.001.
Results.
TPα α α α and TPβ β β β isoforms independently regulate the Gq/ PLCβ β β β and G 12 / Rho signaling systems. U46619 stimulation, with maximal responses generated using 1 µM U46619 ( Figure 1 ; Supplemental Data).
Moreover, both TPα and TPβ also mediated rapid RhoA activation in HEK.TPα and HEK.TPβ cells in response to U46619 stimulation while no such activation was observed in the vehicle-treated cells or in the control non-transfected HEK 293 cells in the presence of U46619 ( Figure 1A ). From concentration-response studies, 10-100 nM U46619 was required for maximal RhoA activation by both TPα and TPβ while timecourse assays confirmed that this was rapid, occurring within 2 min, and sustained for at least 30 min for both TP isoforms ( Figure 1A and 1B). RhoA activation through GPCRs predominantly occurs by coupling to G 12 (Gα 12 /Gα 13 ) members but may also occur through Gq coupling, in certain settings at least [31] [32] [33] .
Herein, over-expression of dominant negative forms of Gα 12 (Gα 12
G228A
), but not of Gαq (Gαq Q209l,D277N ), significantly impaired U46619-mediated RhoA activation through both TPα (p = 0.0011 and p = 0.8011 respectively) and TPβ (p = 0.0043 and p = 0.9235 respectively; Figure 1C ).
To extend these studies, we also examined U46619-mediated stress fibre formation in HEK.TPα and HEK.TPβ cells by monitoring F-actin polymerization and Rho-dependent phosphorylation, and inactivation, of the actin depolymerizing agent cofilin using anti-phospho-cofilin antibodies directed to phosphoSer 3 [34] . Throughout the latter, assays were normalised for total cofilin expression as presented in ) had no significant effect ( Figure 2C ). The Rho kinase inhibitor Y27632 (10 µM) effectively abolished U46619-induced cofilin phosphorylation by both TPα and TPβ (data not shown).
Collectively, these data confirm that both TPα and TPβ can independently couple to both Gq-dependent PLCβ activation to mobilize Ca 2+ from IP 3 -operated intracellular stores, for example, and to G 12 -dependent
RhoA activation and effector coupling leading to cofilin phosphorylation and inactivation and to F-actin polymerization.
The effect of Prostacyclin/cAMP and NO/cGMP on TPα α α α-and TPβ β β β-mediated PLCβ β β β -and RhoA-Signaling.
Amongst the many functional differences identified thus far between the individual TPα and TPβ isoforms [22] , one of the most significant relates to the differential heterologous desensitization of their signaling by the vasodilatory autocoids prostacyclin [21] , prostaglandin (PG) D 2 [27] and nitric oxide [20] . Hence, in view of those differential sensitivities of Gq/PLCβ-mediated signaling by TPα and TPβ to both prostacyclin/cAMP and NO/cGMP [20, 21] , coupled to the well documented inhibitory actions of cAMP and cGMP on Rho-mediated signaling in response to various agents including TXA 2 and thrombin, such as within platelets and vascular smooth muscle [35, 36] , we next investigated the effects of prostacyclin and NO on Cicaprost had no effect on RhoA activation by TPβ, even at 10 µM Cicaprost ( Figure 3A) . Similarly, SIN-1 also significantly impaired U46619-mediated RhoA activation by TPα in a concentration-dependent manner but had no effect on RhoA activation by TPβ, even at 50 µM SIN-1 ( Figure 3B ). While Cicaprost (1 -10 µM) and SIN-1 (5 -50 µM) each significantly impaired U46619-induced F-actin polymerization by both TPα and TPβ, consistent with the inhibitory effects of cAMP/PKA and cGMP/PKG on both the Ca 2+ -dependent and Ca 2+ -independent paths, it was apparent that at lower concentrations both Cicaprost (100 nM) and SIN-1 and the alternative NO donor FK409 also significantly impaired U46619-mediated RhoA activation ( Figure   3C ) and cofilin phosphorylation (data not shown) by TPα but had no effect on signaling by TPβ ( Figure 3C and data not shown).
We have previously established that while both prostacyclin analogues, such as Cicaprost, and NO- Hence, we conclude that, similar to that which occurs for TP-mediated Gq/PLCβ activation, both the
NO and prostacyclin analogues SIN-1 and Cicaprost impair TP-mediated cytoskeletal changes involving
RhoA activation and cofilin phosphorylation in 1 o h.AoSMCs and that they do so, at least in part, by specifically and directly targeting TPα, impairing its downstream signaling. On the other hand, neither vasodilatory agent directly target TPβ. Hence, TPα-and TPβ-mediated RhoA signaling functionally diverge at the point at which prostacyclin and NO affect the RhoA signaling cascade.
Discussion
Much of the molecular events that underlie the complex physiologic processes of platelet aggregation and thrombosis, VSM contraction, migration, proliferation involve the fundamental reorganization of the cellular cytoskeleton [5] . [6, 8, 35, 36] . However, as stated, our data generated in the HEK 293 cell lines over-expressing the individual TPα and TPβ isoforms suggest that such inhibitory responses of prostacyclin and NO are mediated, at least in part, directly at the level of TPα itself rather than at the level of other well documented targets of cAMP/PKA and cGMP/PKG on Rho signaling [35, 36] . Human AoSMCs express both TPα and TPβ isoforms [26, 30] . Hence, through the use of TP isoform-specific siRNA, we sought to determine whether TPα and TPβ independently contribute to U46619-induced RhoA activation and signaling in 1 o h.AoSMCs and to ascertain whether the inhibitory effects of NO and/or Cicaprost may directly target TPα, or indeed TPβ, at the level of the receptor itself and/or in addition to other downstream targets [36] . Under optimized experimental conditions, the specificity and utility of the siRNA TPα and siRNA TPβ reagents were validated whereby we observed effective isoform-specific knock-down of both TPα and TPβ expression and As stated, it is widely held that agents that signal through either cAMP-or cGMP-second messenger systems play a critical counter-balancing / inhibitory affect on RhoA-mediated signaling cascades [35, 36] as well as regulating Rho-mediated transcriptional responses through the serum response factor [40] . In fact within the vasculature, there is a critical reciprocal relationship between RhoA signaling and expression and that of NO-signaling and expression of endothelial nitric oxide synthase (eNOS) [6, 36, 41, 42] . Moreover, in platelets there is a differential effect whereby cAMP/PKA inhibits both the Gq/PLCβ-mediated aggregation and secretion and the G 12 /Rho-mediated shape change while cGMP/PKG signaling inhibits the former Gq/ Ca 2+ dependent mechanism but does not affect the latter RhoA/Ca 2+ independent mechanism [35] . Clearly many of the actions of cAMP and cGMP on RhoA signaling are mediated through their respective second messenger kinases PKA and PKG, respectively [6, 35, 36, 43] and more recently it has been established that this may largely occur through their direct phosphorylation of RhoA itself at an identical site, namely Ser 188 within its hypervariable region [36, 42, 44, 45] . Whilst phosphorylation of RhoA at Ser 188 does not apparently alter its association with either RhoGEFs or RhoGAPs (GTPase activating proteins), it significantly increases its interaction with RhoGDI (GDP dissociation inhibitor) thereby reducing the level of membrane bound
RhoA and impairing its ability to activate its key effectors including Rho Kinases [36, 46] . Moreover, in a recent study investigating NGF-mediated RhoA responses in neuronal PC12 cells, Nusser et al provided in vitro and in vivo evidence to suggest that Ser 188 phosphorylation of RhoA impairs activation of Rho kinase (ROCK 1/2), but does not affect its ability to activate other Rho effectors including rhotekin, mDia-1 and PKN [47] . From their studies, they proposed that Ser 188 phosphorylation of RhoA may act as a 'secondary molecular switch' capable of overriding GTP-elicited activation of certain RhoA effectors, such as ROCK, but directing it to signal with (an)other subset of Rho effectors, perhaps in a cell specific manner. Returning to studies herein on TPα-and TPβ-mediated RhoA signalling, both NO and prostacyclin directly target RhoA phosphorylation at Ser 188 through their regulation of PKG and PKA signaling, respectively (data not shown).
Hence, RhoA-mediated signaling by TPα is subject to regulation by both direct prostacyclin/PKA and NO/PKG-inhibition mediated through their respective phosphorylation of Ser 329 and Ser 331 within the unique C-tail domain of TPα in addition to the more general type of regulation through Ser 188 phosphorylation of RhoA. On the other hand, TPβ is not a direct target for either PKA or PKG phosphorylation or inhibition, but its RhoA mediated signaling would be sensitive to RhoA phosphorylation by either second messenger kinase.
Whilst it has not as yet been established whether the "molecular switch mechanism" resulting from RhoA S188 phosphorylation proposed by Nusser et al [47] to exist in neuronal cells can be extended to other cell/tissue types, such as smooth muscle, it is tempting to speculate.
Hence, as presented in our model (Figure 10 ), we propose that as TPα is directly targeted for inhibition by prostacyclin and NO, its signaling would be fully impaired by either vasodilator beginning at the level of the receptor itself. On the other hand, as TPβ is not subject to direct PKA or PKG phosphorylation, its signaling by prostacyclin or NO may only be regulated at downstream intermediary level(s), such as at the level of RhoA phosphorylation. In the event that the 'phospho-RhoA Ser188 switch mechanism' exists within TXA 2 -responsive VSM or indeed in platelets, RhoA signaling through TPβ may be directed away from one effector system, such as ROCK signaling, in the direction of another effector(s), such as rhotekin, mDia-1 and PKN ( Figure 10 ) as proposed by Nusser et al [47] in the neuronal system, or indeed toward other subset(s) of the many diverse RhoA effectors, perhaps in a cell specific manner. Final clarification as to whether such a mechanism exists will require further detailed investigation.
Hence, in summary TPα-and TPβ-mediated RhoA signaling functionally diverge at the point at which prostacyclin and NO affect the RhoA signaling cascade. These data further support the hypothesis that TPα is the major regulatory TP isoform involved in vascular hemostasis being a direct target for inhibition of both its Gq/PLCβ/Ca 2+ -dependent and G 12 /RhoA/Ca o antibody and stained using FITC-labelled goat anti-rabbit IgG, where cell nuclei were counter stained with propidium iodide. In Panel A, data are representative of 3 independent experiments where a total of 16 independent fields of cells were anyalysed for each TP isoform. It was estimated that there was greater than 70% reduction TPα/TPβ expression in 80% of cells analysed. In Panel B, cells were serum-starved for 20 hr before treatment for 10 min with vehicle or 1 µM U46619 as indicated. Active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (Active RhoA) while cell lysates were analyzed for total RhoA expression, phospho-cofilin and total cofilin expression as indicated. Panels C and D, the cells were serum-starved for 20 hr before treatment for 10 min with vehicle, 1.0 µM Cicaprost or 5.0 µM SIN-1. Thereafter, cells were incubated for 10 min with vehicle (-) or 1 µM U46619. In Panel C, active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody (Upper panels) while cell lysates were analyzed for total RhoA expression (Lower panels). In Panel D, cell lysates were immunoblotted with anti-Phospho cofilin (Upper panels) or anti-cofilin (Lower panels) antibodies. In Panel B, the bar charts to the right signify mean fold changes in Rho activation and cofilin phosphorylation ± S.E.M (n = 3 -6) where basal levels are assigned a value of 1.0. The asterisks indicates that U46619-mediated RhoA activation and cofilin phosphorylation was significantly reduced in the presence of their respective TPα (siRNA TPα ) and TPβ (siRNA TPβ ) siRNAs where * indicates p < 0.05 and p < 0.01, respectively. The bar charts below Panels C and D depict mean reductions (± S.E.M, n = 3 -6) in U46619-mediated Rho activation (C) and cofilin phosphorylation (D) in response to pre-treatment with Sin-1 and Cicaprost, and the asterisks indicate that the level of desensitization was significantly altered in the presence of the siRNA TPα or siRNA TPβ where * and ** indicates p < 0.05 and p < 0.01, respectively. 
